Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.

Engineered live biotherapeutic products (eLBPs) are genetically modified microorganisms being explored as a novel treatment modality for gastrointestinal (GI) diseases. The therapeutic potential is driven by their ability to selectively interact with…

Preview only. Read the full abstract at the source